Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

【ビジネスワイヤ】米女性化粧品ブランドのメアリー・ケイは、オハイオ州コロンバスで開催の高校生向けグローバルＳＴＥＭコンペティション「リジェネロン国際学生科学技術フェア（Ｒｅｇｅｎｅｒｏｎ・ＩＳＥＦ）」に特別賞授与団体として参加したことを発表した。同フェアは、６０カ国以上から約２０００人が参加し、総額９００万ドルを超える賞金や奨学金が与えられるとともに、ＳＴＥ ...

Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” ...

Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying opportunity?

This was the stock's second consecutive day of losses.

Regeneron Pharmaceuticals was outbid in its effort to buy 23andMe by a nonprofit led by the bankrupt genetics testing company’s co-founder. California-based TTAM Research Institute, led by Anne ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the ...

Regeneron said it will acquire 23andMe’s genomics service and its bank of 15 million customers’ personal and genetic data as part of the deal. The pharma giant said it plans to use the 23andMe ...

Lynozyfic’s global sales are projected to reach $707 million by 2031.